Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of recombinant von Willebrand factor prophylaxis in children with severe von Willebrand disease
2020-003304-13Phase 3Active
- Sponsor
- Takeda
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vonicog alfa in von Willebrand disease (VWD), sponsored by Takeda. Primary endpoint: Annualized bleeding rate with intra-patient historical control. Started Oct 2022; status: active.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2020-003304-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003304-13.